Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By

How To Treat Hemophilia: 6 Treatment Options

Medically reviewed by Fatima Sharif, MBBS, FCPS
Updated on November 19, 2026

Key Takeaways

  • Hemophilia is a bleeding disorder that can be managed through several different types of treatments, ranging from factor replacement therapies to newer options like gene therapy.
  • There are six main treatment approaches for hemophilia, including factor replacement, medications that help control bleeding, inhibitor treatments, factor-mimicking medications, rebalancing agents, and gene therapy. Some of these treatments work to prevent bleeds from happening, while others are used to stop bleeding after it has already started.
  • Because treatment needs can vary widely depending on a person's type of hemophilia, severity, and health history, talking with a healthcare provider or visiting a hemophilia treatment center can help you explore which options may work best for you.
  • View all takeaways

Hemophilia has six main treatment options: factor replacement, medications that control bleeding, inhibitor treatments, factor-mimicking medications, rebalancing agents, and gene therapy. Some options prevent bleeds, while others help stop bleeding after it starts.

Hemophilia A involves factor VIII (8), while hemophilia B involves factor IX (9). Other bleeding disorders can involve platelets, von Willebrand factor, or other parts of blood clotting. Without treatment, serious bleeding can harm joints and organs.

In the United States, hemophilia treatment centers bring together specialists who help people plan their care and find support. Here’s what to know about your treatment options.

1

How Does Factor Replacement Work?

Factor replacement gives the body the clotting factor it needs through an intravenous (IV) infusion. They work by replacing the missing clotting factor in the blood. There are two types: standard half-life therapies and extended half-life therapies.

  • Standard half-life therapies are typically infused every one to three days.
  • Extended half-life therapies are designed to stay in the bloodstream longer, so they can be given less often — sometimes just once or twice a week.

How often someone receives factor therapy depends on their condition and treatment plan. Factor therapy may be used in three main ways:

  • Prophylaxis treatment — Regular infusions to help prevent bleeding before it starts
  • On-demand treatment — Infusions given as soon as a bleed starts or after an injury
  • Perioperative treatment — Infusions given before, during, or after a surgery or dental procedure to help prevent heavy bleeding

Some factor replacement therapies are approved by the U.S. Food and Drug Administration (FDA) for all three uses, while others are only approved for one or two.

Recombinant Products

Recombinant products are lab-made clotting factors. A majority of people with hemophilia use them to help their blood clot.

Brands of recombinant factor VIII concentrates to treat hemophilia A include:

Brands of recombinant factor IX concentrates for hemophilia B include:

Brands of recombinant factor concentrates for rare bleeding disorders include:

  • Recombinant factor VIIa (7a) concentrate (NovoSeven RT)
  • Recombinant factor XIIIa (13a)

Plasma-Derived Clotting Factors

Factor replacement concentrates are made from donated human plasma. The plasma is checked for diseases and heated to kill any germs. Alphanate, Humate-P, and Wilate are used to treat hemophilia A and von Willebrand disease.

Profilnine (factor IX complex containing factors II [2], VII, IX and X [10]) and Coagadex (factor X) are examples of other factor replacement concentrates made from human plasma.

Fibrinogen Concentrates, Fresh Frozen Plasma, and Cryoprecipitate

Factor I (1) deficiency can be treated with fibrinogen concentrates such as Fibryga and RiaSTAP. Cryoprecipitate (“cryo”) — a product made from frozen blood plasma — is mainly a backup for urgent, serious bleeding when fibrinogen concentrate isn’t available.

There are fewer products available to treat rare bleeding disorders. These include deficiencies in clotting factors I, II, and V (5), as well as those caused by deficiencies in multiple factors.

Rare bleeding disorders may be treated with fresh frozen plasma or prothrombin complex concentrate, both of which contain a combination of clotting factors. Fresh frozen plasma is often needed in large quantities to be effective.

Cryoprecipitate, as mentioned earlier, may also be used, but unlike the other two multifactor products mentioned, cryoprecipitate does not undergo treatment to kill viruses.

Among the treatments listed above, recombinant clotting factors are typically the most expensive. However, they are also considered the safest option because they are made without human plasma, which eliminates the risk of bloodborne infections.

2

What Other Medications Help Control Bleeding?

Nonfactor replacement therapies are hemophilia treatments that support clotting or prevent bleeding in other ways.

Antifibrinolytics

Antifibrinolytics are drugs that prevent bleeding by preventing the breakdown of clots. These medications may be recommended to improve healing or help with excessive menstrual bleeding.

Aminocaproic acid comes in oral and IV forms. Cyklokapron is IV tranexamic acid. Oral tranexamic acid is also available.

Hormones

Desmopressin is a human-made version of the hormone vasopressin. It can be used to treat mild hemophilia A and some types of von Willebrand disease, depending on the person’s response.

Desmopressin is believed to work by increasing the levels of von Willebrand factor and factor VIII in the blood. Desmopressin is available as an injection (sold as DDAVP).

Stimate (desmopressin acetate) nasal spray was recalled in 2020. The FDA approved its return in 2026, and U.S. availability was planned to start in October 2026. Check with a pharmacy for current stock. Stimate shouldn’t be used for type 2B von Willebrand disease.

Hormonal contraceptives, such as the birth control pill or intrauterine devices (IUDs), can help control excessive menstrual bleeding in some individuals with bleeding disorders.

Vitamin K

In some people, bleeding disorders are related to vitamin K deficiency. This can lead to a deficiency of multiple clotting factors, such as factors II, VII, IX, and X. Vitamin K may be taken orally or injected.

3

How Are Inhibitors Treated?

People with inhibitors can use bypassing agents, immune tolerance treatment, or certain nonfactor medications.

Inhibitors are antibodies (immune proteins) that attack and destroy replacement clotting factors. The body creates inhibitors when the immune system recognizes infused factor treatments as foreign substances and starts to destroy them.

Inhibitors can block factor replacement, but newer nonfactor medications can still help prevent bleeds. About 30 percent of people with severe hemophilia A develop inhibitors. It’s less common for people with hemophilia B to develop inhibitors — about 5 percent — but inhibitors can be harder to treat in those with hemophilia B.

Treatment for people with inhibitors can be complicated. Sometimes, a higher dose of a clotting factor may help. If it doesn’t, other treatments are available.

Bypassing Agents

Bypassing agents help to form a clot without the need for factor VIII or factor IX.

Activated prothrombin complex concentrate (Feiba) contains a combination of clotting factors to help treat and prevent bleeds. NovoSeven RT and Sevenfact are recombinant factor VIIa concentrates approved to treat people with hemophilia A and hemophilia B with inhibitors.

Immune Tolerance Induction

Inhibitors themselves can be treated in some people via immune tolerance induction (ITI). ITI involves taking large, regular doses of replacement factor for months or years. The goal of this treatment is to “train” the immune system to stop making inhibitors.

ITI is successful in 70 percent to 80 percent of people with hemophilia A. However, this treatment requires a large time and money commitment.

4

What Are Factor-Mimicking Medications?

These medications copy some of the work of clotting factor VIII to help prevent bleeding in hemophilia A.

Biologics are special treatments made from living sources, like cells or proteins. Emicizumab-kxwh (Hemlibra) is a biologic drug made of a monoclonal antibody (laboratory-made immune protein). It can be used to treat hemophilia A in people with and without inhibitors.

Emicizumab-kxwh is believed to work by activating the coagulation process by connecting factors IXa (9a) and X. Since emicizumab-kxwh isn’t a clotting factor, it can help prevent bleeding even in people with inhibitors.

This medication is given as a subcutaneous (under the skin) injection.

5

When Are Rebalancing Agents Used?

Rebalancing agents are a type of nonfactor therapy used to treat hemophilia A and B with and without inhibitors. They work by restoring the balance between factors that help the blood clot and factors that prevent the blood from clotting.

Concizumab-mtci (Alhemo) and marstacimab-hncq (Hympavzi) help blood clot better by blocking a protein called tissue factor pathway inhibitor, which normally slows down clotting. Fitusiran (Qfitlia) works by blocking antithrombin, a protein that usually slows clotting. This helps the blood clot better.

These medications are injected under the skin. Concizumab-mtci, fitusiran, and marstacimab-hncq have different approved uses and age limits. Fitusiran can prevent bleeding in people ages 12 and older with hemophilia A or B, with or without inhibitors.

These medications may raise the risk of dangerous blood clots, so careful dosing and monitoring matter.

6

Can Gene Therapy Treat Hemophilia?

Gene therapy can help some adults with hemophilia A or B, even though the availability of specific treatments has changed.

Gene therapy is a treatment that provides a working copy of the defective gene causing hemophilia. With a working copy of the gene, a person with hemophilia may be able to make the missing clotting factor on their own.

Etranacogene dezaparvovec-drlb (Hemgenix) is a one-time IV gene therapy for certain adults with hemophilia B. Doctors check whether a person is eligible and monitor them after treatment. Valoctocogene roxaparvovec-rvox is no longer commercially available in the U.S.

What Should You Do if Someone With Hemophilia Gets Cut?

Wash a small cut, press firmly with clean gauze, and cover it. If bleeding won’t stop, call the person’s care team.

Get emergency help for heavy bleeding or a head injury. Follow the person’s emergency treatment plan.

How Does Treatment Differ for Mild, Moderate, and Severe Hemophilia?

Mild hemophilia may need treatment mainly after injuries or before surgery. Moderate or severe hemophilia often calls for regular treatment to prevent bleeding.

Having an emergency kit on hand can be helpful. Treatment also depends on a person’s bleeding history, joint health, and whether they have inhibitors.

References
  1. Treatment of Hemophilia — U.S. Centers for Disease Control and Prevention
  2. Types — National Bleeding Disorders Foundation
  3. Hemophilia Treatment Centers (HTCs) — U.S. Centers for Disease Control and Prevention
  4. Current Treatments — National Bleeding Disorders Foundation
  5. Hemophilia — World Federation of Hemophilia
  6. The High Price of Hemophilia — American Society of Hematology
  7. Products Licensed in the US — National Bleeding Disorders Foundation
  8. Treatment of Rare Factor Deficiencies in 2016 — Hematology, ASH Education Program
  9. Other Treatment Products — The Hemophilia, von Willebrand Disease & Platelet Disorders Handbook
  10. Treatment for Hemophilia — The Hemophilia, von Willebrand Disease & Platelet Disorders Handbook
  11. Ferring Pharmaceuticals Announces Return of STIMATE — National Bleeding Disorders Foundation
  12. Stimate (Desmopressin Acetate) Nasal Spray — U.S. Food and Drug Administration
  13. Vitamin K Deficiency in Neonates and Adults — StatPearls
  14. How Do I Prevent and Treat Bleeds When I Have an Inhibitor? — National Bleeding Disorders Foundation
  15. Inhibitors — World Federation of Hemophilia
  16. Immune Tolerance To Treat an Inhibitor — The Hemophilia, von Willebrand Disease & Platelet Disorders Handbook
  17. Biologics (Biologic Medicine) — Cleveland Clinic
  18. MASAC Document 268 — Recommendation on the Use and Management of Emicizumab-Kxwh (Hemlibra) for Hemophilia A With and Without Inhibitors — National Bleeding Disorders Foundation
  19. Hemostatic Rebalancing Therapy — World Federation of Hemophilia
  20. Small Cuts and Scrapes — The Hemophilia, von Willebrand Disease & Platelet Disorders Handbook
  21. Hemophilia: What To Know About Your Treatment Options — Mayo Clinic Press
Share this article
A MyHemophiliaTeam Member

We can now add Gene therapy to the list of treatments for Hemophilia B....Thanks CSL Behring... I will be closely following their clinical progression. As a severe Hemophilia A patient I can't wait… read more

All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
17,031 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
17,031 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In

Thank you for subscribing!

Become a member to get even more

See answer